# Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

> **NCT01493115** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 18 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine HOE901
- **DRUG:** Insulin glargine - New formulation HOE901

## Key facts

- **NCT ID:** NCT01493115
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01493115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01493115, "Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01493115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*